JPH01132525A - 抗ウイルス及び抗腫瘍効果を有する、動物及び人間用の治療薬の製造方法、並びに該方法によって得られる薬剤 - Google Patents
抗ウイルス及び抗腫瘍効果を有する、動物及び人間用の治療薬の製造方法、並びに該方法によって得られる薬剤Info
- Publication number
- JPH01132525A JPH01132525A JP63257448A JP25744888A JPH01132525A JP H01132525 A JPH01132525 A JP H01132525A JP 63257448 A JP63257448 A JP 63257448A JP 25744888 A JP25744888 A JP 25744888A JP H01132525 A JPH01132525 A JP H01132525A
- Authority
- JP
- Japan
- Prior art keywords
- inorganic salt
- azo
- pyridine
- diamino
- antiviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 10
- 230000000840 anti-viral effect Effects 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000003814 drug Substances 0.000 title description 5
- 229940079593 drug Drugs 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 9
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract 4
- 229920000856 Amylose Polymers 0.000 claims abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims abstract 2
- 239000008101 lactose Substances 0.000 claims abstract 2
- 239000002674 ointment Substances 0.000 claims abstract 2
- 239000006188 syrup Substances 0.000 claims abstract 2
- 235000020357 syrup Nutrition 0.000 claims abstract 2
- 229940099259 vaseline Drugs 0.000 claims abstract 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 4
- 150000001642 boronic acid derivatives Chemical class 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004327 boric acid Substances 0.000 abstract description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 230000002155 anti-virotic effect Effects 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- -1 For example Chemical class 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- CLRSZXHOSMKUIB-UHFFFAOYSA-M benzenediazonium chloride Chemical compound [Cl-].N#[N+]C1=CC=CC=C1 CLRSZXHOSMKUIB-UHFFFAOYSA-M 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- UBTRQPAMLAFXTO-UHFFFAOYSA-N boric acid;3-phenyl-2-(pyridin-2-yldiazenyl)-1h-pyridine-2,6-diamine Chemical compound OB(O)O.C=1C=CC=NC=1N=NC1(N)NC(N)=CC=C1C1=CC=CC=C1 UBTRQPAMLAFXTO-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8702446A NL8702446A (nl) | 1987-10-14 | 1987-10-14 | Werkwijze ter bereiding van een veterinair- en humaanmedisch preparaat met antivirale en antitumorale werking, alsmede het in farmaceutisch toepasbare vorm gebrachte preparaat. |
| NL8702446 | 1987-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01132525A true JPH01132525A (ja) | 1989-05-25 |
Family
ID=19850759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63257448A Pending JPH01132525A (ja) | 1987-10-14 | 1988-10-14 | 抗ウイルス及び抗腫瘍効果を有する、動物及び人間用の治療薬の製造方法、並びに該方法によって得られる薬剤 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0312132B1 (enExample) |
| JP (1) | JPH01132525A (enExample) |
| CN (1) | CN1041695A (enExample) |
| AT (1) | ATE84418T1 (enExample) |
| AU (1) | AU619767B2 (enExample) |
| CA (1) | CA1338489C (enExample) |
| DE (1) | DE3877499T2 (enExample) |
| DK (1) | DK574588A (enExample) |
| ES (1) | ES2042715T3 (enExample) |
| GR (1) | GR3009556T3 (enExample) |
| IE (1) | IE60506B1 (enExample) |
| IL (1) | IL87867A (enExample) |
| NL (1) | NL8702446A (enExample) |
| NZ (1) | NZ226360A (enExample) |
| ZA (1) | ZA887181B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101305168B (zh) | 2005-11-15 | 2010-05-12 | 日锻汽门株式会社 | 装入制冷剂空心提升阀及其制造方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596777B1 (en) | 1997-05-29 | 2003-07-22 | Mcneil-Ppc, Inc. | Moisture containing compositions that are spreadable onto and adherable to biomembranes |
| RU2354384C1 (ru) * | 2007-12-28 | 2009-05-10 | Михаил Владимирович Кутушов | Применение органических красителей в качестве средства для лечения онкологических заболеваний |
-
1987
- 1987-10-14 NL NL8702446A patent/NL8702446A/nl not_active Application Discontinuation
-
1988
- 1988-08-24 DE DE8888201797T patent/DE3877499T2/de not_active Expired - Fee Related
- 1988-08-24 EP EP19880201797 patent/EP0312132B1/en not_active Expired - Lifetime
- 1988-08-24 AT AT88201797T patent/ATE84418T1/de not_active IP Right Cessation
- 1988-08-24 ES ES88201797T patent/ES2042715T3/es not_active Expired - Lifetime
- 1988-09-26 ZA ZA887181A patent/ZA887181B/xx unknown
- 1988-09-28 NZ NZ226360A patent/NZ226360A/xx unknown
- 1988-09-28 IL IL87867A patent/IL87867A/xx not_active IP Right Cessation
- 1988-09-30 CA CA000579070A patent/CA1338489C/en not_active Expired - Fee Related
- 1988-10-12 AU AU23663/88A patent/AU619767B2/en not_active Ceased
- 1988-10-14 CN CN88107207A patent/CN1041695A/zh active Pending
- 1988-10-14 JP JP63257448A patent/JPH01132525A/ja active Pending
- 1988-10-14 IE IE311688A patent/IE60506B1/en not_active IP Right Cessation
- 1988-10-14 DK DK574588A patent/DK574588A/da not_active Application Discontinuation
-
1993
- 1993-03-29 GR GR930400677T patent/GR3009556T3/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101305168B (zh) | 2005-11-15 | 2010-05-12 | 日锻汽门株式会社 | 装入制冷剂空心提升阀及其制造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ226360A (en) | 1990-08-28 |
| DK574588A (da) | 1989-04-15 |
| EP0312132B1 (en) | 1993-01-13 |
| AU619767B2 (en) | 1992-02-06 |
| DE3877499D1 (de) | 1993-02-25 |
| DE3877499T2 (de) | 1993-06-03 |
| CA1338489C (en) | 1996-07-30 |
| DK574588D0 (da) | 1988-10-14 |
| AU2366388A (en) | 1989-06-01 |
| ZA887181B (en) | 1989-05-30 |
| EP0312132A2 (en) | 1989-04-19 |
| IL87867A (en) | 1992-11-15 |
| ATE84418T1 (de) | 1993-01-15 |
| CN1041695A (zh) | 1990-05-02 |
| NL8702446A (nl) | 1989-05-01 |
| EP0312132A3 (en) | 1990-04-25 |
| IL87867A0 (en) | 1989-03-31 |
| IE883116L (en) | 1989-04-14 |
| IE60506B1 (en) | 1994-07-27 |
| GR3009556T3 (enExample) | 1994-02-28 |
| ES2042715T3 (es) | 1993-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106659711A (zh) | 呈现长期稳定性的褪黑素注射剂的持久制剂 | |
| JPH11503460A (ja) | ウィルスおよび癌の増殖を阻止するｎ−クロロフェニルカルバメートおよびｎ−クロロフェニルチオカルバメート含有医薬組成物 | |
| CN101522692A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药 | |
| EP1970372B1 (en) | Salts of 9-oxoacridine-10-acetic acid with 1-alkylamno-1-desoxy-polyols | |
| JPH01132525A (ja) | 抗ウイルス及び抗腫瘍効果を有する、動物及び人間用の治療薬の製造方法、並びに該方法によって得られる薬剤 | |
| US4002741A (en) | Meglumine complex fungicidal polyene macrolide antibiotic compositions and treatment method | |
| AR018198A1 (es) | Soluciones estables de mitoxantrona, procedimiento para prepararlas, utilizacion de dichas soluciones para la preparacion de medicamentos y losmedicamentos de aplicacion de dichas soluciones para el tratamiento de enfermedades cancerosas | |
| JPH06501449A (ja) | 癌またはウイル性疾患の治療におけるトリニトロベンゼン類またはカルミン酸の使用 | |
| CN117717550A (zh) | 基于千金藤素与牛磺酸复合物的抗菌药物及其制备方法 | |
| RU2135474C1 (ru) | Соли 1-дезокси-1-n-метиламиногексаспиртов с n-акридонуксусной кислотой, обладающие иммуномодулирующей активностью, и лекарственное средство на их основе | |
| CN102079715B (zh) | 一种二元酯酸的赖氨酸盐化合物,其制备方法和药物应用 | |
| US4153691A (en) | Analgesic and anti-inflammatory compositions | |
| CA1285226C (en) | Compositions containing a 2,4-diamino-pyrimidine and sulphadimidine | |
| KR20230016199A (ko) | 글루타티온을 포함하는 조성물 및 치료 방법 | |
| CN1147321C (zh) | 一种制备左旋苏糖酸盐化合物或络合物的方法 | |
| AU740642B2 (en) | Pharmaceutical compositions containing cinchonine dichlorhydrate | |
| RU2238086C2 (ru) | Новая лекарственная форма n-(4-нитро-2-феноксифенил) метансульфонамида, способ ее получения и применения | |
| RU2181051C1 (ru) | Способ получения инъекционного средства на основе вещества с р-витаминной активностью | |
| US4537908A (en) | Herpes II treatment | |
| US3923805A (en) | Propoxyphene derivative | |
| CN103980228B (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药 | |
| EP0384722B1 (en) | Chemical compositions | |
| MX2013014605A (es) | Complejo recristalizado de clorhidrato de enrofloxacina dihidratado, y metodo para obtener el mismo. | |
| Sapeika | Some pharmacological aspects of the sulphonamides, penicillin and streptomycin | |
| CN104140422A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药 |